Gland Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Manappuram Finance Ltd, Tube Investments of India Ltd, Five-Star Business Finance Ltd, Eternal Ltd are among the other stocks to see a surge in volumes on BSE today, 02 April 2026.

Gland Pharma Ltd witnessed volume of 67579 shares by 10:45 IST on BSE, a 12.19 times surge over two-week average daily volume of 5544 shares. The stock dropped 2.92% to Rs.1,656.80. Volumes stood at 9059 shares in the last session.

Manappuram Finance Ltd saw volume of 22.55 lakh shares by 10:45 IST on BSE, a 9.59 fold spurt over two-week average daily volume of 2.35 lakh shares. The stock dropped 1.25% to Rs.252.35. Volumes stood at 5.18 lakh shares in the last session.

Tube Investments of India Ltd recorded volume of 1.32 lakh shares by 10:45 IST on BSE, a 9.17 times surge over two-week average daily volume of 14346 shares. The stock lost 2.69% to Rs.2,500.80. Volumes stood at 3338 shares in the last session.

Five-Star Business Finance Ltd saw volume of 5.83 lakh shares by 10:45 IST on BSE, a 4.82 fold spurt over two-week average daily volume of 1.21 lakh shares. The stock dropped 1.58% to Rs.354.45. Volumes stood at 35421 shares in the last session.

Eternal Ltd saw volume of 103.96 lakh shares by 10:45 IST on BSE, a 3.63 fold spurt over two-week average daily volume of 28.68 lakh shares. The stock dropped 4.88% to Rs.225.15. Volumes stood at 18.89 lakh shares in the last session.

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1676.6, down 1.75% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.68% on the day, quoting at 24597.8. The Sensex is at 79386.06, down 0.79%.Gland Pharma Ltd has eased around 11.05% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 3.44% in last one month and is currently quoting at 23005.5, up 0.23% on the day. The volume in the stock stood at 50035 shares today, compared to the daily average of 84591 shares in last one month.

The PE of the stock is 23.67 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc.

Brimonidine Tartrate Ophthalmic Solution, 0.025% is indicated for the relief of redness of the eye. According to IQVIA data, the product recorded US sales of approximately $39 million for the twelve months ended September 2025.

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.

The company reported a 27.7% increase in consolidated net profit to Rs 261.48 crore on a 22.5% rise in net sales to Rs 1,695.36 crore in Q3 FY26 as compared with Q3 FY25.

The counter slipped 3.26% to Rs 1,736.60 on the BSE.

Powered by Capital Market - Live News

Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lumify Ophthalmic Solution, 0.025%, of Bausch & Lomb Inc.

This Product is indicated to relieve redness of the eye.

Powered by Capital Market - Live News